title: Could targeting secretory leukocyte protease inhibitor be an effective therapeutic option to prevent infections in acute liver failure?
authors.affiliation: Department of Hepatology, St Mary's Campus, Imperial College London, London, UK.
authors.forename: Lucia A
authors.initials: LA
authors.lastname: Possamai
authors.forename: Wafa
authors.initials: W
authors.lastname: Khamri
authors.forename: Evangelos
authors.initials: E
authors.lastname: Triantafyllou
authors.forename: Julia A
authors.initials: JA
authors.lastname: Wendon
authors.forename: Mark R
authors.initials: MR
authors.lastname: Thursz
authors.forename: Charalambos G
authors.initials: CG
authors.lastname: Antoniades
mesh_terms: D006801:Humans; D017114:Liver Failure, Acute / Q000276:immunology* / Q000517:prevention & control; D058990:Molecular Targeted Therapy / Q000379:methods; D018570:Risk Assessment; D012307:Risk Factors; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000276:immunology*; D018805:Sepsis / Q000276:immunology* / Q000517:prevention & control; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology*
chemical_list: C506814:SLPI protein, human; D053481:Secretory Leukocyte Peptidase Inhibitor